Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma
| Autor: | Andrea D’Amico, Jacek Najda, Malgorzata Sobczyk-Kruszelnicka, Sławomir Blamek, Bożena Jochymek, Michał Radwan, Leszek Miszczyk, Łukasz Dolla, Wlodzimierz Mendrek, Maria Saduś-Wojciechowska, Jerzy Holowiecki, Krzysztof Ślosarek, Wojciech Leszczyński, Sebastian Giebel, Tomasz Czerw, Grzegorz Woźniak |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Melphalan
Adult medicine.medical_specialty Transplantation Conditioning medicine.medical_treatment Urology Neutropenia Transplantation Autologous Tomotherapy 03 medical and health sciences 0302 clinical medicine Bone Marrow medicine Humans Multiple myeloma Very Good Partial Response Transplantation Hematopoietic cell business.industry Hematopoietic Stem Cell Transplantation Hematology Total Marrow Irradiation Middle Aged medicine.disease Treatment Outcome 030220 oncology & carcinogenesis business Multiple Myeloma 030215 immunology medicine.drug |
| Zdroj: | Bone marrow transplantation. 56(6) |
| ISSN: | 1476-5365 |
| Popis: | The goal of this phase II trial was to evaluate safety and efficacy of a tandem autologous hematopoietic cell transplantation (auto-HCT) using sequentially total marrow irradiation (TMI) at the dose of 12 Gy (4 Gy on days -3, -2, and -1) and melphalan 200 mg/m2 for patients with multiple myeloma (MM). TMI was performed using helical tomotherapy. Additional "boosts" (total 24 Gy) were applied for patients with active lesions as revealed by PET-FDG. Fifty patients with median age 58 years (41-64 years) were included and received tandem auto-HCT. TMI resulted in absolute neutropenia in all patients. Grade 3 infections were reported in 30% patients. Other toxicities were rare. Proportion of patients who achieved at least very good partial response increased from 46% before the first auto-HCT to 82% after tandem transplantation. Complete remission rates changed from 10% to 42%, respectively. The probabilities of overall and progression-free survival at 5 years were 74% and 55%, respectively. No patient died without progression. We conclude that conditioning with TMI ± PET-guided "boosts" represents personalized treatment approach in MM and is characterized by very good toxicity profile. Tandem auto-HCT using TMI in sequence with high-dose melphalan appears safe with encouraging early efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink